rheumatoid arthritis

Nov 05, 2024

Prolong Pharmaceuticals Secures FDA Fast Track for PP-007 in Stroke Therapy Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has been granted Fast Track designation by the FDA for the treatment of a...

Oct 04, 2024

The past decade experienced a lot of shuffling in the Rheumatoid arthritis market. The journey started with the approvals of disease-modifying anti-rheumatic drugs (DMARDs). Several conventional DMARDs constituting methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, biologics with initial entrants bei...

Oct 02, 2024

Beyond the shadow of a doubt, the Rheumatoid arthritis treatment market has witnessed strides of improvement during the last few years. There was a time when treatment for rheumatoid arthritis was confined to Non-steroidal anti-inflammatory drugs (NSAIDs) and steroids, which could only address pain and swelling. Ho...

Sep 06, 2024

Hidradenitis suppurativa is a chronic inflammatory skin disease that affects the hair follicles and apocrine sweat glands. Hidradenitis suppurativa affects approximately 1% of the population, with women being more commonly affected than men. It often begins after puberty, usually in the 20s or 30s. In 2023, the ...

Oct 11, 2023

The human immune system has a magnificent defense system that works continuously to protect the body from numerous infections and outside invaders. Maintaining a healthy immune response through the intricate interplay of cells, chemicals, and signaling pathways is essential for general health and well-being. Immuno...

Mar 16, 2022

Cannabidiol (CBD) is one of the 120 cannabinoids present naturally in cannabis plants. After tetrahydrocannabinol (THC), Cannabidiol is the second most prevalently available cannabinoid. Cannabidiol, an important component of medicinal marijuana, is either directly from the hemp plant or synthesized in a laboratory...

Jan 25, 2022

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Aug 20, 2020

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Jun 16, 2020

The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in...

Apr 14, 2020

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...